ProposalCentral link

The SU2C Catalyst Research Grant Program with support from Zentalis Pharmaceuticals endeavors to support research investigating the use of Wee1 inhibitors for treating a variety of cancer types. The most talented and promising researchers across institutions are encouraged to assemble into a collaborative multi-institutional team, forming an optimal configuration of expertise needed to solve key cancer problems that could be supported by foundational knowledge of Wee1 biology. Mechanisms to foster collaborations within and among the Team will be employed – an approach that promotes the sharing of information and a goal-oriented focus on measurable milestones of progress. SU2C believes that this unique Team will advance scientific research in the interests of improved long-term oucomes for patients. The Research Team will benefit from SU2C’s structure and oversight through which a multi-disciplinary team will come together with support to focus on a discrete set of aims. The bi-annual progress review practiced by SU2C ensures that milestones and deliverables are met and will keep the project focused on its goals. The Research Team is supported by a grant from Zentalis Pharmaceuticals.